Skip to main content
SpringerLink
Log in

5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer

  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Oncolytic herpes viruses are attenuated, replication-competent viruses that selectively infect, replicate within, and lyse cancer cells and are highly efficacious in the treatment of a wide variety of experimental cancers. The current study seeks to define the pharmacologic interactions between chemotherapeutic drugs and the oncolytic herpes viral strain NV1066 in the treatment of pancreatic cancer cell lines. The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor cell) ranging from 0.01 to 1.0 with or without 5-fluorouracil (5-FU) or gemcitabine. Synergistic efficacy was determined by the isobologram and combination-index methods of Chou and Talalay. Viral replication was measured using a standard plaque assay. Six days after combination therapy, 76% of Hs 700T cells were killed compared with 43% with NV1066 infection alone (MOI = 0.1) or 0% with 5-FU alone (2 βmol/L) (P < .01). Isobologram and combination-index analyses confirmed a strongly synergistic pharmacologic interaction between the agents at all viral and drug combinations tested (LD5 to LD95) in the three cell lines. Dose reductions up to 6- and 78-fold may be achieved with combination therapy for NV1066 and 5-FU, respectively, without compromising cell kill. 5-FU increased viral replication up to 19-fold compared with cells treated with virus alone. Similar results were observed by combining gemcitabine and NV1066. We have demonstrated that 5-FU and gemcitabine potentiate oncolytic herpes viral replication and cytotoxicity across a range of clinically achievable doses in the treatment of human pancreatic cancer cell lines. The potential clinical implications of this synergistic interaction include improvements in efficacy, treatment-associated toxicity, tolerability of therapeutic regimens, and quality of life. These data provide the cellular basis for the clinical investigation of combined oncolytic herpes virus therapy and chemotherapy in the treatment of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. Ca Cancer J Clin 2005;55:10–30.

    Article  PubMed  Google Scholar 

  2. Wolff R, Abbruzzese J, Evans D. Neoplasms of the exocrine pancreas. In: Kufe D, Pollock R, Weichselbaum R, et al, eds. Holland Frei Cancer Medicine. 6th ed. Canada: BC Decker; 2003.

    Google Scholar 

  3. Picozzi VJ, Traverso LW. The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin North Am 2004;13:663–674.

    Article  Google Scholar 

  4. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68–73.

    Article  PubMed  CAS  Google Scholar 

  5. Brennan MF. Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin North Am 2004;13:555–566.

    Article  Google Scholar 

  6. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 2001; 8:123–132.

    Article  PubMed  CAS  Google Scholar 

  7. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreasd616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.

    Article  PubMed  CAS  Google Scholar 

  8. Nitecki SS, Sarr MG, Colby TV, Van Heerden JA. Longterm survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59–66.

    Article  PubMed  CAS  Google Scholar 

  9. Andreansky S, Soroceanu L, Flotte ER, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997;57:1502–1509.

    PubMed  CAS  Google Scholar 

  10. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A 1995;92:1411–1415.

    Article  PubMed  CAS  Google Scholar 

  11. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replicationcompetent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999;1:162–169.

    Article  PubMed  CAS  Google Scholar 

  12. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999;59:2055–2058.

    PubMed  CAS  Google Scholar 

  13. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938–943.

    Article  PubMed  CAS  Google Scholar 

  14. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000;4:580–588.

    Article  PubMed  CAS  Google Scholar 

  15. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12–21.

    Article  PubMed  CAS  Google Scholar 

  16. Bennett JJ, Kooby DA, Delman K, et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000;78:166–174.

    Article  PubMed  CAS  Google Scholar 

  17. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325–1334.

    PubMed  CAS  Google Scholar 

  18. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replicationcompetent multimutated herpes simplex virus 1. Cancer Res 1995;55:4752–4756.

    PubMed  CAS  Google Scholar 

  19. Advani SJ, Chmura SJ, Weichselbaum RR. Radiogenetic therapy: On the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol 1997;24:633–638.

    PubMed  CAS  Google Scholar 

  20. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998;5:160–165.

    Article  PubMed  CAS  Google Scholar 

  21. Stanziale SF, Petrowsky H, Joe JK, et al. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 2002;132:353–359.

    Article  PubMed  Google Scholar 

  22. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004;18:1001–1003.

    PubMed  CAS  Google Scholar 

  23. Longnecker R, Chatterjee S, Whitley RJ, Roizman B. Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture. Proc Natl Acad Sci U S A 1987;84:4303–4307.

    Article  PubMed  CAS  Google Scholar 

  24. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 2002;13:1213–1223.

    Article  PubMed  CAS  Google Scholar 

  25. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2002;21:8a.

    Google Scholar 

  26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.

    Article  PubMed  CAS  Google Scholar 

  27. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TCR, ed. Synergism and Antagonism in Chemotherapy. New York: Academic Press, 1991, pp 61–102.

    Google Scholar 

  28. Chou JCTC. Dose-effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, antagonism, lowdose risk, receptor-ligand binding and enzyme kinetics. Manual and Software. Cambridge, U.K.: Biosoft Cambridge; 1987.

    Google Scholar 

  29. Chou J. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC, eds. Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press; 1991, pp 223–244.

    Google Scholar 

  30. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517–1524.

    Article  PubMed  CAS  Google Scholar 

  31. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999;10:3013–3029.

    Article  PubMed  CAS  Google Scholar 

  32. Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999;5:1517–1522.

    PubMed  CAS  Google Scholar 

  33. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000;2:588–595.

    Article  PubMed  CAS  Google Scholar 

  34. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001;12:999–1010.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY

    David P. Eisenberg M.D., Prasad S. Adusumilli M.D., Karen J. Hendershott M.D., Zhenkun Yu M.D., Ph.D., Michael Mullerad M.D., Mei-Ki Chan B.S. & Yuman Fong M.D.

  2. Preclinical Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York

    Ting-Chao Chou Ph.D.

Authors
  1. David P. Eisenberg M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prasad S. Adusumilli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen J. Hendershott M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenkun Yu M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Mullerad M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mei-Ki Chan B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ting-Chao Chou Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuman Fong M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuman Fong M.D..

Additional information

Supported in part by training grant T 32 CA09501 (D.P.E. and K.J.H.), AACR-AstraZeneca Cancer Research and Prevention fellowship (P.S.A), grants RO1 CA 76416 and RO1 CA/DK80982 (Y.F.) from the National Institutes of Health, grant BC024118 from the U.S. Army (Y.F.), grant IMG0402501 from the Susan G. Komen Foundation (Y.F.), and grant 032047 from Flight Attendant Medical Research Institute (Y.F.).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenberg, D.P., Adusumilli, P.S., Hendershott, K.J. et al. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 9, 1068–1079 (2005). https://doi.org/10.1016/j.gassur.2005.06.024

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2005.06.024

Key words

Search

Navigation